Abstract
Background
The Janus stent releases Tacrolimus from reservoirs located at the abluminal stent surface without any polymer. In stable coronary lesions the stent did not show relevant antiproliferative effects. Since Tacrolimus provides antiproliferative and antiinflammatory properties, we sought to investigate the efficacy of the Tacrolimus eluting Janus stent in acute coronary syndrome lesions with a more pronounced inflammatory cell reaction compared to stable coronary artery lesions.
Methods
Patients with acute coronary syndrome (STEMI or NSTEMI) undergoing cardiac catheterization and stent implantation were enrolled in this prospective registry. Primary outcome measure was in-stent late lumen loss at 6 months. There were two pre-specified subgroups based on presence or absence of high-pressure post-dilation (HPPD) with a balloon ≥0.25 mm larger than the delivery balloon.
Results
Sixty patients were enrolled. In 34 patients HPPD was performed. Reference diameter was 2.85 ± 0.57 mm. Stented length was 30.8 ± 23.8 mm in HPPD and 19.7 ± 7.3 mm in non-HPPD group. For the total population in-stent late loss was 0.92 ± 0.80 mm and binary restenosis rate 32.6%. Late loss (1.09 ± 0.74 mm Vs. 0.64 ± 0.83 mm) and binary restenosis rate (37.0% Vs. 25.0%) were higher in the HPPD subgroup compared to lesions in non-HPPD. The angiographic evidence of thrombus was associated with a higher late loss. Restenotic pattern was occlusive in 40%, diffuse in 33% and focal in 27%.
Conclusion
The use of the Tacrolimus eluting Janus stent in acute coronary syndrome lesions was associated with a high late lumen loss, a high angiographic restenosis rate and a mainly occlusive or diffuse pattern of restenosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barlis P, Virmani R, Sheppard MN, Tanigawa J, Di Mario C (2007) Angiographic and histological assessment of successfully treated late acute stent thrombosis secondary to a sirolimus-eluting stent. Eur Heart J 28:1675
Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S (2007) Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 15:2426–2434
Matter CM, Rozenberg I, Jaschko A, Greutert H, Kurz DJ, Wnendt S, Kuttler B, Joch H, Grünenfelder J, Zünd G, Tanner FC, Lüscher TF (2006) Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 48:286–292
Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020–1029
Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB (1999) Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100:1872–1878
Mohacsi PJ, Tüller D, Hulliger B, Wijngaard LJ (1997) Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 16:484–492
Morice MC, Bestehorn HP, Carrié D, Macaya C, Aengevaeren W, Wijns W, Dubois C, de Winter R, Verheye S, Hoffmann S, Pachinger O, di Marco C (2006) Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention 2:45–52
Silber S, Borggrefe M, Böhm M, Hoffmeister HM, Dietz R, Ertl G, Heusch G (2007) Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES). Der Kardiologe 1:84–111
Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:989–997
Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998–1008
Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701–705
Wöhrle J, Nusser T, Langenwalder S, Hombach V, Kochs M (2008) Carbon coated stent in patients with acute coronary syndromes. Clin Cardiol (in press)
Wöhrle J (2007) Stent thrombosis in the era of drug-eluting stents. Herz 32:411–418
Wöhrle J, Nusser T, Kestler HA, Kochs M, Hombach V (2007) Comparison of the slow-release polymer-based paclitaxel-eluting taxus-express stent with the bare-metal express stent for saphenous vein graft interventions. Clin Res Cardiol 96:70–76
Conflict of interests
There is no conflict of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rinker, A., Nusser, T., Grossmann, G. et al. Angiographic results of a Tacrolimus-eluting stent in acute coronary syndrome lesions. Clin Res Cardiol 98, 89–93 (2009). https://doi.org/10.1007/s00392-008-0726-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-008-0726-x